Translational research progress in malignant lymphoma
10.3760/cma.j.issn.1009-9921.2017.02.004
- VernacularTitle:恶性淋巴瘤临床转化研究进展
- Author:
Ning DING
;
Jun ZHU
- Keywords:
Lymphoma;
Translational research;
Immunotherapy;
Pathogenesis;
American Society of Hematology Annual Meeting
- From:
Journal of Leukemia & Lymphoma
2017;26(2):74-75
- CountryChina
- Language:Chinese
-
Abstract:
Rituximab in the combination of CHOP regimen has been widely used as the standard treatment of several kinds of B cell non-Hodgkin lymphoma (B-NHL),but there are still about 1/3 of the late B-NHL patients become primary and secondary resistant to the drug.Recently,many translational research progress in malignant lymphoma promoted the development of promising candidate drugs for the treatment of lymphoma.The advances in translational research field were summarized in this manuscript.
